Literature DB >> 27671674

Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.

Curtis A Clark1,2, Harshita B Gupta2, Gangadhara Sareddy3,4, Srilakshmi Pandeswara2, Shunhua Lao2, Bin Yuan2,5, Justin M Drerup1,2, Alvaro Padron2, José Conejo-Garcia6, Kruthi Murthy1,2, Yang Liu2,7, Mary Jo Turk8, Kathrin Thedieck9, Vincent Hurez2, Rong Li1,3,5, Ratna Vadlamudi1,3,4, Tyler J Curiel10,2,3.   

Abstract

PD-L1 antibodies produce efficacious clinical responses in diverse human cancers, but the basis for their effects remains unclear, leaving a gap in the understanding of how to rationally leverage therapeutic activity. PD-L1 is widely expressed in tumor cells, but its contributions to tumor pathogenicity are incompletely understood. In this study, we evaluated the hypothesis that PD-L1 exerts tumor cell-intrinsic signals that are critical for pathogenesis. Using RNAi methodology, we attenuated PD-L1 in the murine ovarian cell line ID8agg and the melanoma cell line B16 (termed PD-L1lo cells), which express basal PD-L1. We observed that PD-L1lo cells proliferated more weakly than control cells in vitro As expected, PD-L1lo cells formed tumors in immunocompetent mice relatively more slowly, but unexpectedly, they also formed tumors more slowly in immunodeficient NSG mice. RNA sequencing analysis identified a number of genes involved in autophagy and mTOR signaling that were affected by PD-L1 expression. In support of a functional role, PD-L1 attenuation augmented autophagy and blunted the ability of autophagy inhibitors to limit proliferation in vitro and in vivo in NSG mice. PD-L1 attenuation also reduced mTORC1 activity and augmented the antiproliferative effects of the mTORC1 inhibitor rapamycin. PD-L1lo cells were also relatively deficient in metastasis to the lung, and we found that anti-PD-L1 administration could block tumor cell growth and metastasis in NSG mice. This therapeutic effect was observed with B16 cells but not ID8agg cells, illustrating tumor- or compartmental-specific effects in the therapeutic setting. Overall, our findings extend understanding of PD-L1 functions, illustrate nonimmune effects of anti-PD-L1 immunotherapy, and suggest broader uses for PD-L1 as a biomarker for assessing cancer therapeutic responses. Cancer Res; 76(23); 6964-74. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27671674      PMCID: PMC5228566          DOI: 10.1158/0008-5472.CAN-16-0258

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling.

Authors:  Yonghao Yu; Sang-Oh Yoon; George Poulogiannis; Qian Yang; Xiaoju Max Ma; Judit Villén; Neil Kubica; Gregory R Hoffman; Lewis C Cantley; Steven P Gygi; John Blenis
Journal:  Science       Date:  2011-06-10       Impact factor: 47.728

Review 2.  Autophagy at the crossroads of catabolism and anabolism.

Authors:  Jasvinder Kaur; Jayanta Debnath
Journal:  Nat Rev Mol Cell Biol       Date:  2015-07-15       Impact factor: 94.444

3.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

4.  Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.

Authors:  Sara R Pedersen; Maria R Sørensen; Søren Buus; Jan P Christensen; Allan R Thomsen
Journal:  J Immunol       Date:  2013-09-09       Impact factor: 5.422

Review 5.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Curr Opin Immunol       Date:  2012-01-09       Impact factor: 7.486

6.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Authors:  Dos D Sarbassov; Siraj M Ali; Shomit Sengupta; Joon-Ho Sheen; Peggy P Hsu; Alex F Bagley; Andrew L Markhard; David M Sabatini
Journal:  Mol Cell       Date:  2006-04-06       Impact factor: 17.970

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB.

Authors:  Carmine Settembre; Roberto Zoncu; Diego L Medina; Francesco Vetrini; Serkan Erdin; SerpilUckac Erdin; Tuong Huynh; Mathieu Ferron; Gerard Karsenty; Michel C Vellard; Valeria Facchinetti; David M Sabatini; Andrea Ballabio
Journal:  EMBO J       Date:  2012-02-17       Impact factor: 11.598

9.  Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction.

Authors:  Shengdian Wang; Jürgen Bajorath; Dallas B Flies; Haidong Dong; Tasuku Honjo; Lieping Chen
Journal:  J Exp Med       Date:  2003-04-28       Impact factor: 14.307

10.  The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.

Authors:  Peter M K Westcott; Kyle D Halliwill; Minh D To; Mamunur Rashid; Alistair G Rust; Thomas M Keane; Reyno Delrosario; Kuang-Yu Jen; Kay E Gurley; Christopher J Kemp; Erik Fredlund; David A Quigley; David J Adams; Allan Balmain
Journal:  Nature       Date:  2014-11-02       Impact factor: 49.962

View more
  119 in total

1.  Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer.

Authors:  Ruohua Chen; Xiang Zhou; Jianjun Liu; Gang Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-09       Impact factor: 9.236

2.  Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway.

Authors:  Shaojia Wang; Jiajia Li; Jie Xie; Fei Liu; Yachen Duan; Yong Wu; Shenglin Huang; Xianghuo He; Ziliang Wang; Xiaohua Wu
Journal:  Oncogene       Date:  2018-04-30       Impact factor: 9.867

3.  In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related.

Authors:  Yanhua Bai; Ting Guo; Xiaozheng Huang; Qi Wu; Dongfeng Niu; Xinqiang Ji; Qin Feng; Zhongwu Li; Kennichi Kakudo
Journal:  Virchows Arch       Date:  2018-04-12       Impact factor: 4.064

4.  Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.

Authors:  Xiaodong Wang; Xiaohui Yang; Chang Zhang; Yang Wang; Tianyou Cheng; Liqiang Duan; Zhou Tong; Shuguang Tan; Hangjie Zhang; Phei Er Saw; Yinmin Gu; Jinhua Wang; Yibi Zhang; Lina Shang; Yajuan Liu; Siyuan Jiang; Bingxue Yan; Rong Li; Yue Yang; Jie Yu; Yunzhao Chen; George Fu Gao; Qinong Ye; Shan Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-11       Impact factor: 11.205

5.  Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors.

Authors:  Renata Boldrini; Maria Debora De Pasquale; Ombretta Melaiu; Marco Chierici; Giuseppe Jurman; Maria Chiara Benedetti; Nunzio C Salfi; Aurora Castellano; Paola Collini; Cesare Furlanello; Vito Pistoia; Loredana Cifaldi; Monica Terenziani; Doriana Fruci
Journal:  Oncoimmunology       Date:  2018-12-13       Impact factor: 8.110

6.  The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.

Authors:  Yue Zou; Mohammad M Uddin; Sveta Padmanabhan; Yan Zhu; Pengli Bu; Ales Vancura; Ivana Vancurova
Journal:  J Biol Chem       Date:  2018-08-22       Impact factor: 5.157

7.  Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.

Authors:  Zhitao Dong; Boyi Liao; Weifeng Shen; Chengjun Sui; Jiamei Yang
Journal:  Dig Dis Sci       Date:  2019-08-13       Impact factor: 3.199

8.  PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer.

Authors:  Dagmar Kollmann; Thomas Schweiger; Stefan Schwarz; Desislava Ignatova; Yun-Tsan Chang; Gerrit Lewik; Sebastian F Schoppmann; Wolfram Hoetzenecker; Walter Klepetko; Emmanuella Guenova; Konrad Hoetzenecker
Journal:  Oncoimmunology       Date:  2017-08-18       Impact factor: 8.110

9.  Efficient development and expression of scFv recombinant proteins against PD-L1 surface domain and potency in cancer therapy.

Authors:  Muhammad Kalim; Keying Liang; Muhammad Saleem Iqbal Khan; Jinbiao Zhan
Journal:  Cytotechnology       Date:  2019-05-16       Impact factor: 2.058

Review 10.  A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.

Authors:  Caroline E Nunes-Xavier; Javier C Angulo; Rafael Pulido; José I López
Journal:  Curr Urol Rep       Date:  2019-01-15       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.